WHO ICTRP trial
REFINE - a randomised control trial testing reduced intensity immunotherapy…
ISRCTN79455488 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN79455488 |
|---|---|
| Public title | REFINE - a randomised control trial testing reduced intensity immunotherapy across different cancers |
| Scientific title | REduced Frequency ImmuNE checkpoint inhibition in cancers: A multi-arm phase II basket protocol testing reduced intensity immunotherapy across different cancers |
| Primary sponsor | University College London |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | United Kingdom;England;Scotland;Wales |
| Conditions | Treatment of multiple cancer types which are local advanced or metastatic using immune checkpoint inhibition therapies in adult patients already receiving immune checkpoint inhibitors Cancer |
| Interventions | As part of standard of care patients can receive infusions of immune checkpoint inhibitors once every 4 weeks. Patients with renal cancer receive ipilimumab + nivolumab (once every 4 weeks), and patients with melanoma receive ipilimumab +… |
| Registration date | Jul 27, 2022 |
| Target size | 360 |
| Secondary IDs | 2021-002060-47;NCT04913025;RF01, IRAS 298208, CPMS 50169 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: